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Background: Arterial hypertension is a major health concern. It affects more than a billion of 
people worldwide and is known as a “silent killer”, which impact the patients’ therapeutic 
adherence and thus their treatment efficiency. A potential way to improve the therapeutic 
adherence is the use of blood pressure self-measurement in combination with new 
technologies such as the mobile health (mhealth). 
Aim: Proof of concept study aimed at developing and evaluating, in terms of functionality, 
feasibility and performance, a digital platform to improve the self-management of 
hypertensive patients. 
Methods: The platform was developed in collaboration with the “Connected Health” team 
from Nokia Belgium. Once the platform was ready to be tested, 8 patients were recruited. 
The patients were added in the platform and they were given a blood pressure monitor 
device (Withings BPM-801) in order to perform their self-measurements. The devices are to 
be used with a smartphone application, the “Nokia Health Mate” and all the data collected in 
the smartphone application are sent to the platform, where a healthcare professional can 
manage them. The patients have to take their blood pressure twice a week during two 
months (8 weeks) and they will receive reminders, warnings or encouraging messages 
according to their blood pressure or measurements performed or not. 
Analysis: The platform was shown to be functional and efficient with 187 out of 223 
measures correctly transferred (83,85%). A database issue occurred at the initiation but was 
rapidly corrected and another issue occurred at the end of the study but was not related to 
the platform itself. The patient compliance to the protocol was relatively high with 223 out of 
252 measures done (88,5%). Regarding the blood pressure data, the study sample was too 
small to see significant differences but some slight changes can be seen in several patients. 
For the feasibility, 7 out of 8 patients found this system very helpful and were ready to extend 
this practice. 
Conclusion: The platform need to be more robust in order to prevent the issues 
encountered and need some slight adaptation but it was showed to be functional, efficient 
and useful for the patients. A further study might then be envisaged in order to test the 
potential benefit in poor or non-adherent hypertensive patient. 
Keywords: arterial hypertension, adherence, self-measurement, connected device, 
home blood pressure monitoring 
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a. Arterial Hypertension 
 
Arterial hypertension is defined by an increase of the arterial systolic pressure above 140mmHg 
and/or an increase of the arterial diastolic pressure above 90mmHg [1]. This increase must be 
confirmed by several measures of the blood pressure [2]. More recently the new American 
guidelines from the American College of Cardiology and the American Heart Association 
(ACC/AHA) revised downward the threshold of arterial hypertension by defining an elevated 
blood pressure when above 130/80 mmHg regardless the age [3]. However, the 2018 European 
Society of Cardiology (ESC) and European Society of Hypertension (ESH) guidelines define 
a systolic blood pressure target less than 140mmHg for the majority of patients and less than 
130mmHg for the patients younger than 65 years [4]. The total number of hypertensive people 
reaches one billion worldwide and arterial hypertension is more prevalent in African countries 
(46%) than in high income countries (35%) [2]. 
 
About 95% of arterial hypertension cases are of essential origin which means that the etiology 
is unknown. Nevertheless some risk factors can be distinguished such as age (>60 years old), 
obesity, absence of physical activity or high sodium chloride intake [2]. Secondary forms of 
arterial hypertension also exist. Those forms can usually be cured and include: iatrogenic 
hypertension due to the uptake of alcohol or drugs such as oral contraceptives, cyclosporine, 
tacrolimus, illicit drugs (cocaine, amphetamines); hypertension due to renal artery stenosis and 
“adrenal” hypertension as a consequence of an adrenal tumour or hyperplasia with a 
hypersecretion of aldosterone, catecholamine or cortisol. “Masked” and “white coat” 
hypertensions should also be distinguished. The masked hypertension shows normal results 
of blood pressure at the physician’s office but high blood pressure in self-measurement at 
home while the white coat hypertension shows normal results in self-measurement but high 
blood pressure at the physician’s office [2, 3]. 
 
The diagnosis should include the hypertension state, assess the presence of secondary forms 
of arterial hypertension and evaluate the cardiovascular risks. The measurement of blood 
pressure at the office is performed with auscultatory or oscillometric semiautomatic 
sphygmomanometers placed at the upper arm. Beside the office’s measurement it is also 
possible to perform ambulatory blood pressure monitoring (ABPM) or home blood pressure 
monitoring (HBPM). Those techniques allow multiple measurements away from the medical 
environment [1]. ABPM is the measurement of blood pressure for a period of 24 hours or 
more with the use of automatic and wearable manometer. The measurement is usually 
performed every 15 minutes during the day and every 30 minutes overnight. HBPM consists 
of the auto-measurement of blood pressure at home during at least 3 consecutive days 
following the European Union (EU) guidelines [1]. These measurements are done with arm 
or wrist devices, but these latter are less recommended [5]. In the HBPM, the measurements 
should be done at least twice a day (in the morning and in the evening). In the long-term 
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follow-up, less frequent measurements can be performed aimed at reinforcing adherence. This 
provides data from the everyday routine which are more reliable [2]. These two lasts types of 
measurement are useful for patient’s follow-up. The ABPM was considered as the best way 
to measure the blood pressure at home. However, the HBPM is more and more considered as 
a complementary method to the ABPM. Monaco et al. (2016) compared the two methods and 
demonstrate that HBPM cannot substitute the ABPM. Indeed, there was not a high degree of 
agreement between the two methods. The discrepancies come from the fact that in the HBPM 
there could be inaccuracy in patients’ measurements. Patients’ training and the development 
of the HBPM technology (e.g. devices connected with smartphones) may reduce this 
discrepancies [6].  
 
Once the measurements are done, a therapeutic decision can be taken. If the blood pressure is 
lower than 130/80mmHg, no intervention is needed. If it is in the high average (130-139 and 
85-89mmHg) a primary prevention should be considered such as reducing the risk factors. If 
it is above 140/90mmHg and confirmed, anti-hypertensive drugs should be considered (Figure 
1). 
 
Figure 1. Table adapted from the ESC 2013 guidelines [1] containing the therapeutic decisions that can be 
taken in regards with the patient's condition. 
Those values correspond to the Office Blood Pressure Measurement but they are not the same 
for ABPM and HBPM. In Europe, the threshold is 130/80mmHg for ABPM (corresponding 
to the mean of day and night measures) and 135/85mmHg for HBPM [2]. Anti-hypertensive 
drugs are divided in different classes: diuretics, beta blockers, calcium channel blockers, 
angiotensin-converting- enzyme inhibitor and sartans (angiotensin II receptor antagonists). 
An association of those drugs may be also envisaged. Alpha blockers, vasodilators and central 
anti-hypertensive drugs are less indicated [7]. 
 
This proof of concept study consists of developing and testing a digital platform to be 
combined with the HBPM technology and is a precursor of a further study in which we will 
evaluate the impact of this platform on the therapeutic adherence among hypertensive patients 
that are non- or poor adherent. 
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b. Therapeutic Adherence 
 
Therapeutic adherence is defined as “the process by which patients take their medication as 
prescribed”. When patients did not follow their medication scheme correctly, there are called 
“non-adherent”. Different terms such as compliance, persistence, and concordance are often 
used interchangeably to define different aspect of this process (e.g. concordance is used to 
describe the relationship between the general practitioner and the patient) and that may lead 
to confusion. Vrijens et al. (2012) thus proposed a new taxonomy. They defined “Adherence 
to medication” and “Management of adherence” as “the process by which patients take their 
medication as prescribed” and “the process of monitoring and supporting patients’ adherence 
to medication by health care systems, providers, patients, and their social network” 
respectively. There are different forms of non-adherence: absence of initiation by the patient; 
poor execution (the patient delays, omits or take extra doses); the patient discontinues his 
treatment (non persistence) (Figure 2) [8].  
 
The non-adherence can be unintentional or intentional. The unintentional cause is the 
forgetfulness while the intentional causes may be having other things to do, intentional 
decision to omit the treatment, a lack of information or emotional factors. The adherence is 
poor when the medication’s frequency of intake is high thus simple dosing (one pill a day) 
helps to improve the adherence [9]. The new taxonomy proposed by Vrijens et al. (2012) also 
emphasized the physician’s role in the management of adherence (Figure 2). There are some 
hurdles leading to poor adherence and these hurdles may be addressed to the physician instead 
of the patient. Indeed, according to Devine et al. (2018) [10], the most frequent reason of non- 
or poor adherence is the patient’s lack of motivation driven by depression which can be 
translated into physician’s perspective as an “Inadequate effort to address depression”. 
There’s then a need for the physician to screen depression and give appropriate treatment to 
the patient. Another frequent reason of non- or poor adherence is the patient’s fear about a 
potential adverse event which can also be translated as an “Inadequate transmittal of 
information about medication”. Tackling this problem and thus emphasizing the physician’s 
role is a way to improve the adherence [10]. Non-adherence might also be driven by the 
disease itself, by the treatment, by a bad patient-physician relationship, by the treatment’s cost 
and/or the financial status of the patient or by the system of treatment reimbursement. 
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Figure 2. Illustration from Vrijens et al. [8] showing the process of adherence and the actors involved in 
the management of adherence. 
 
A low adherence to medication is generally observed in hypertensive patients. Such 
conclusion has been obtained by different methods like the High Performance Liquid 
Chromatography (HPLC) urine analysis showing that 25% of a 208 hypertensive patients’ 
cohort are totally or partially non-adherent [11] or by self- reported non adherence using a 
scale like the “Morisky Medication Adherence Scale” (MMAS) where 40.7% of 897 
participants were showed non-adherent [12]. Other questionnaires exist to measure the 
adherence such as the Hill-Bone compliance scale, the SEAMS (Self-efficacy for Appropriate 
Medication Use Scale), the BMQ (Brief Medication Questionnaire), the MARS (Medication 
Adherence Rating Scale) or  the ARMS (Adherence to Refills and Medication Scale) [13]. 
These questionnaires also cover the measurement of adherence for certain disease other than 
arterial hypertension like coronary heart diseases, diabetes, psychosis, acquired immune 
deficiency syndrome (AIDS), osteoporosis and smoking cessation. Most of them show a good 
internal consistency reliability with a high Cronbach's alpha coefficient (>0.8) [13]. There are 
other ways to measure the adherence like calculating the “Proportion of Days Covered” (PDC) 
or the “Medication Prescription Ratio” (MPR) which are defined by “the number of doses 
dispensed in relation to a dispensing period”. The PDC can have a maximum value of 1 
(complete adherence) whereas the MPR can have a value above 1 if there is any oversupply of 
the medication [14]. A way to improve the adherence in hypertensive patient is the use of 
HBPM [15]. However the successfulness of such methods remains unclear in the long-term 
[16]. 
 
The relationship between the adherence and blood pressure control in arterial hypertension has 
been studied. Bramley et al. performed a retrospective study from 1999 to 2002 in the US on a 
population of 840 hypertensive patients taking a monotherapy. This study showed that the 
highly adherent patients are more likely to have a controlled blood pressure than the medium 
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or low adherent ones (Figure 3) and that a higher total number of medication is associated with 
a lower control of blood pressure [17]. However, only 43% of highly adherent patients achieved 
a controlled blood pressure (<140/90mmHg). 
 
 
Figure 3. Figure from Bramley et al. [17] showing the percentage of patients achieving blood pressure 
control (<140/90mmHg) according to their level of adherence to the medication. 
 
The relation between the adherence to antihypertensive drugs and the risk of cardiovascular 
events was assessed by Perreault et al. [18]. They made a retrospective study on a cohort of 83 
267 patients treated with antihypertensive agents between 1999 and 2004. The rate of 
cardiovascular events was determined with respect to the adherence level to antihypertensive 
drugs which was calculated using the MPR. It was then found that a higher level of adherence 
was associated with a risk reduction of cardiovascular events [18]. 
 
The adherence was also studied according to the class of antihypertensive agents [19]. The 
meta-analysis performed by Kronish et al. found that there was a relationship between the 
adherence to antihypertensive agents and the drug class. Indeed, the diuretics and beta-blockers 
were associated with a lower adherence compared to the angiotensin-II receptors blockers and 
angiotensin conversion enzyme inhibitors which are associated with a better adherence.  These 
differences are probably due to the side effects brought by the drug class (e.g. the diuretics 
induce and increase urinary frequency) or due to the patients’ beliefs about medication [19]. 
This might then be factors to modify in order to increase the adherence. 
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The American Society of Hypertension (ASH) published in 2010 a position paper emphasizing 
the importance of therapeutic adherence and persistence to control blood pressure [20]. They 
identified the problem’s scope of a lack of adherence and they reviewed scientific background 
to support the importance of adherence while taking medication. Eventually, they provided 
some recommendations such as to focus on the clinical outcomes to maintain a goal blood 
pressure over time; to empower, inform the patients and make them more active in their 
treatment, they have to learn how to take care of themselves; to implement a team approach to 
deliver a collaborative care and to be more patient-centred; to advocate for health authorities to 
increase the awareness about the importance of therapeutic adherence [20].  
  
c. Digital Health and telemonitoring 
 
With the development of science and technology occurs a new way to diagnose and follow 
diseases. Digital health, e-health or telemedicine have appeared and with it mobile health 
(mHealth) and connected medical devices [21]. The mHealth consists of using portable 
devices with digital applications in order to follow patient’s health condition. With billions of 
mobile phone users, such way to enhanced healthy behaviours has to be considered [22]. There 
are different types of devices like the “Smartphone-connected rhythm monitoring devices”, 
the “Wireless and wearable devices” and even “Implantable and ingestible sensors” (Figure 
4). With that type of technology, a question to ask is “Are the patients ready to use these 
connected devices and will it improve their condition?” Several telemedicine trials show 
encouraging results with improvement of patients’ condition [21]. Indeed, Kim et al. (2016) 
[23] performed a trial with hypertensive patients distributed between a monitoring and a 
control group in order to evaluate the influence of a self-monitoring program on the health 
behaviours, the therapeutic adherence and the control of blood pressure. The monitoring group 
had an improvement of the health condition, showing that hypertensive patients are receptive 
to that type of program. There was no difference in their therapeutic adherence (measured 
with a Morisky scale). However the patients were already relatively adherent (with a median 
Morisky score at 7.0) and probably had a higher health literacy because of working in a 
hospital. This results in a selection bias. Further study is then needed to evaluate the impact 




Figure 4. Chart from the IQVIA 2017 report “The Growing Value of Digital Health” showing different 
tools in the field of digital health. 
 
To have a better management of the arterial hypertension, software for self-interpretation of 
blood pressure measurement results were created to work with connected devices. These 
softwares are based on an algorithm that will help the users (the patients) to interpret their 
blood pressure results. The patients have to enter their personal information such as the age, 
the weight and height in order to calculate their Body Mass Index (BMI), their medication 
scheme, their comorbidities, and then they can enter their values of self-measurement of blood 
pressure. The software will then check the data and reject the abnormal values (in the case of 
the Hy-result software, a systolic blood pressure below 60mmHg and a diastolic blood 
pressure below 40mmHg are considered abnormal). A blood pressure mean will be calculated 
and messages will be sent to the patients whether or not they have to go to their general 
practitioner or to adapt their medication schedule. Such softwares have been evaluated and 
have been proven to be at least as accurate as the physician’s assessment [24]. 
 
Nevertheless the healthcare professionals remain reluctant to this kind of technology. Despite 
being more personalized for the patient and its ability to share easily the information about 
diseases, there are still some hurdles to pass like lack of confidence in such technology, legal 
issues concerning data protection or reimbursement issues [25]. There might also be a legal 
liability issue if a patient die while the general practitioner received the patient’s data but 
didn’t react to an abnormal value. Moreover, this type of technology needs a social dimension 
to be effective and it needs to be in harmony with what matters to people. To assess this need 
of social dimension, Greenhalg et al. (2015) performed a 3-phase study. The first phase 
consisted of an interview of technology and service providers. The second phase was an 
ethnographic study of patients in order to get information about their lives with a disease. For 
the last phase, they made workshops with patients and technology and service providers in 
12  
order to make them interact, identify the challenges and have new ideas. Both patients and 
providers found out that this kind of technology need to be customizable to meet the users’ 
requirements. It has also been found that service providers are stuck with standard packages 
and have to deal with it. A greater pledge between service and technology providers is then 
required. Finally, patients emphasized that service providers have to interact more with them 
and create more personal relationships. In brief, a human effort is needed to improve the user’s 
understanding and involvement in such technology [26]. 
 
The ESC took a position to enhance the e-health and to tackle these hurdles. They will play a 
pro-active role and developed an action plan that includes and covers: implementation of e-
health; education and training; regulation and quality control; data security and 
confidentiality; emphasizing the research and cost-effectiveness; solving the reimbursement 
issue and assessing the benefits and risks of e-health. There is also a more specific issue with 
the mHealth. Indeed, there are hundred thousands of Apps available that have been 
downloaded millions of times but there is a lack of distinction between a medical App and a 
lifestyle App, there is an issue about privacy, confidentiality and data use, healthcare providers 
are then unsure about this technology. The ESC will then be a key stakeholder and works with 
the other stakeholder such as the patients’ organization, health professionals, authorities and 
App developers to improve the global quality of these Apps. This mHealth is a way to move 
from care to prevention [25]. 
 
Regarding the costs, Kaambwa et al. performed a cost-effectiveness analysis of the 
TASMINH2 study which evaluate the effect of telemonitoring and self-management in the 
control of arterial hypertension. This study compared the use of automated 
sphygmomanometer and some equipment to transmit the measures to the usual care for 12 
months. It was found out that the use of automated sphygmomanometers induced a reduction 
in blood pressure by 5.4/2.7 mmHg, made the patients take more medications and made them 
change their treatment at least once [27]. The cost-effectiveness analysis found an incremental 
cost effectiveness ratio (ICER) of 1891€ per QALY gained (Quality Adjusted Life Years) in 
men and an ICER of 5733€ per QALY gained in women. The self-management is then more 
costly than usual care but it provides a better quality of life (QoL) due to a decrease of 
cardiovascular events and is still more cost-effective than usual care when looking from a long 
term period of 35 years with a willingness to pay (WTP) threshold of 23 000€ to 35 000€ per 
QALY gained. These results show that the self-management of arterial hypertension with the 
help of telemonitoring reduce the blood pressure but is also cost-effective when compared to 









III. Specific aims 
 
In collaboration with the “Connected Health” team from Nokia Belgium, the ACTO research 
group of the University of Namur, Faculty of Medicine, developed a digital platform, the 
« Enablement Suite », to improve self-management of hypertensive patients, especially the 
non-adherent ones. The current study is a proof of concept phase aimed to evaluate the 
feasibility, usability and performance of such a platform in view of future clinical trials to be 




a. Literature review 
 
The Pubmed database was consulted with the following key words: “arterial hypertension”; 
“adherence”; “self-measurement”; “HBPM”; “connected device”; “intervention”. The articles 
older than 10 years were generally excluded.  
 
The French website “Haute Autorité de Santé” has also been consulted in order to find general 
information about arterial hypertension. 
 
b. Design and study sample 
This trial is a proof of concept study on hypertensive patients. The web platform “Suite” was 
developed by Nokia with the collaboration of the promotors from the Namur University. After 
an approval by the ethics committee from the Ambroise Paré hospital (Mons), 8 hypertensive 
patients are recruited at the hospital from the consultation of Doctor Delmotte, following 
several inclusion and exclusion criteria (Table 1), in order to test the platform in combination 
with the connected device BPM1 from Nokia. Patients will have to measure their blood 
pressure during 2 months. The arterial hypertension condition is based on their medical dossier 
and the prescription of anti-hypertensive compounds. According to the AHA 
recommendations, hypertensive patients presenting arrhythmia can’t participate in this trial 







                                                     
1 https://health.nokia.com/eu/fr/blood-pressure-monitor 
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Inclusion criteria Exclusion criteria 
- Patients from at least 18 years 
old 
 
- Patients who have a smartphone 
able to run the platform and that 
allows access to Internet 
 
 
- Patients who are treated with at 
least one anti-hypertensive drug 
- Patients with cognitive disorders 
 
- Patients without capability to 
follow a 2 months protocol 
 
- Patients who do not understand 
French and unable to understand 
the informed consent 
 
- Patients included in another trial 
 
- Patients with blood pressure above 
200/110mmHg 
 
- Patients presenting significant 
arrhythmia 
Table 1. Inclusion and exclusion criteria for participation in the study. 
 
c. Platform development 
 
The HBPM is performed using connected devices from Nokia: the BPM device (Withings BP-
801). These devices were provided by Nokia and they are to be used with a smartphone 
application, the “Nokia Health Mate” (available on Apple and Android smartphones), with 
which the patients will be able to register the measurements (Figure 5). There is no digital 
interface on the devices, which make them unable to perform the measurements without a 
smartphone. During the follow-up period, in combination with those devices, the patients also 
get an access to the digital platform developed by Nokia and ACTO in order to follow their 
blood pressure and receive comments or advices (Figure 6). This platform contains one 
questionnaire at their inclusion in the study to collect their socio- demographic factors (gender, 
age, social status …), their clinical factors (treatments, comorbidities…) (Appendix 1) and a 











Figure 5. Nokia Health Mate smartphone application. 
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Figure 6. Summary of the whole system developed. 
The platform also records their blood pressure values, the date and the hour of the measures. 
It sends warnings and messages to the patients. We developed 4 types of warnings: 
 
- the measures are not performed 
- there is a technical error 
- abnormal values are detected 
- warnings related to non-adherence to the protocol 
 
The technical error may occur if the patient did not place the device correctly or move during 
the measurement.  
 
The values are considered abnormal if there are under 90/50mmHg or above 200/110mmHg. 
These warnings are sent to encourage the patients to repeat the measurement or advise them 
to contact their general practitioner or their specialist (Appendix 3). Indeed this is only a 
monitoring tool and the general practitioners remain the only people able to treat the patient 
in case of an elevated blood pressure. Therefore in such case the patients are advised to contact 
them for a check-up or a refill if they are lacking of antihypertensive drugs. 
 
In this platform, three types of accounts are available: epertension-admin, epertension-config 
and epertension-expert. Screenshots of the different tools present in the platform are available 
in appendix 5. 
 
The “epertension-admin” account is used to add healthcare professionals and patients to the 
platform and gather them in “Care group” so that each professional can see the results from his 
patients and has no access to other patients from other professionals. Some “Tracking limits” 
were established that can be personalized by the physician if needed. These tracking limits are 
related to a color code which helps the physician to see quickly how his patients’ blood pressure 
is. The red is used for blood pressure measures that are outside the limits (>135/85mmHg or 
<100/60mmHg), yellow is used for blood pressure measures that are in the limits but almost 
outside (between 100/60mmHg and 110/75mmHg or between 120/80mmHg and 
135/85mmHg) and green is used for blood pressure measures that are within the limits 
(110/75mmHg to 120/80mmHg). The tracking limits established in the admin account can be 
personalized in the expert account for each patient, allowing then a more personalized follow-
up of blood pressure according to the patient condition (Figure 7). 
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Figure 7. Tracking limits as seen in the admin account (A) and in a patient’s profile in the expert account 
(B). The color code is visible next to the patients measures (C). 
 
The “epertension-config” account is used to define different settings for the admin and expert 
accounts such as the questionnaire that will be submitted to the patients or the trackers that the 
admin and expert account can use like blood pressure, blood glucose, oxygen saturation and so 
on (Appendix 5). 
 
The “epertension-expert” account is the account used by healthcare professionals. This account 
allows them to add their patients in the system as well as the “epertension-admin” account and 
to see their patients’ profile. In the patient’s profile, the latest measurements are shown as well 
as their answers to the questionnaires. The blood pressure measurements can be seen as a list 
or they can be plotted in a chart. The healthcare professionals also receive some alerts, called 
“cases” that are related to the alerts that the patients receive. A case is created if the patient is 
not compliant to the protocol, if the patient took more measures than asked or if the patient’s 
blood pressure is out of range. The importance of these case is identified by a color code: green 
is for too much measurements than what was asked or a lack of measures during the first part 
of the week; orange is for less measurements than what was asked at the end of the week and 
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Figure 8. Color code on the “Case” page from the expert account. 
 
 
d. Patients’ inclusion and follow-up 
 
Hypertensive treated patients presenting at the consultation of arterial hypertension of the 
Ambroise Paré hospital and at the Dr Delmotte’s private office are invited to participate to this 
proof of concept study. Due to a delay in the recruitment some patients were also recruited 
outside the Dr Delmotte’s consultations. The patients are informed about the conduct of the 
trial and they receive an informed consent form to read at home. If the patients agree to 
participate, they are invited to come at a training session at the Ambroise Paré hospital. The 
patients coming from outside Dr Delmotte’s consultations were seen in the place which they 
wanted. 
 
During this training session, the investigator asked to each patient if they have any questions 
concerning the protocol or the inform consent form. The inform consent form is then signed by 
both the investigator and the patient who is then registered in the system. Firstly the investigator 
helped the patients to create an account on the “Nokia Health Mate” app on their smartphones. 
Secondly he created a patient account on the web platform and linked both accounts. The 
patients are then trained on how to use the device along with the app and how to answer to the 
general information questionnaire. Once these steps are done, the patient may return to home 
with the device. 
 
The patients are contacted by phone during the period of the trial. These phone calls to the 
patients are done during: 
 
- The first week 
- At the end of the first month 
- At the end of the second month 
18  
These calls are done by the research team in order to identify if they face any issue like a non-
working device or difficulties to remember the use of the suite. Patients are also able to contact 
the research team at any time in case of problems. The patients’ feedback is also collected at 
the end of the trial. 
 
e. Blood pressure measurements 
 
Patients were instructed to perform their self-measurements at home, at least 2 days a week, 
2 times in the morning and 2 times in the evening. This schedule is in alignment with the 
guidelines from the ESH, that recommends a minimum of 3 days a week of measurements or 
1 or 2 measurements a week in case of a long term follow-up [29]. A third measurement is 
asked if the second measure performed is significantly higher or lower than the first one (more 
than 20mmHg of difference in the systolic blood pressure). It is indeed expected that some 
stress can occur during the first measure. The platform collects all the raw data, meaning that 
in case of a third measure, all of them will be kept but the data are also computed in order to 
make the mean between the second and third measure (Figure 9). The first measures should 
be recorded no later than Wednesday evening and the second measures should be recorded no 
later than Sunday evening. A message is sent to the patient each time that the measures are 
not recorded on Wednesday or Sunday evening to remind them to measure their blood 
pressure. This reminder has the objective to test if it can improve their adherence. A message 


























Figure 9. “Niveau de pression artérielle” (A) are the computed data and “Tension artérielle” (B) are the 
raw data in a patient profile. More details for the computed data can be obtained by clicking on them. 
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Patients were instructed to perform their self-measurements in a seated position, after few 
minutes of relaxing and to avoid talking during the cuff’s inflation. A second measurement 
has to be executed directly after the first one. The cuff has to be placed around the upper arm, 
few centimetres above the elbow and the arm has to rest on a table during the measurement. 
All the information about the measurement’s schedule and the use of the device are resumed 
in a patient leaflet received at the training session (Appendix 6). 
 
f. Privacy and confidentiality 
 
Patients’ data will be collected only when they have read and signed the informed consent given 
to them at the inclusion visit (Appendix 4). 
Patients’ data will remain confidential and will be fully anonymised in case of publication. 




The primary endpoint of this study is to identify the convenience of the Suite in terms of 
applicability and functionality. 
 
Secondary endpoints are: 
 
- Patients’ feedback at the end of the 2 months. A questionnaire (Appendix 2) is 
addressed to the patients aimed to collect their level of satisfaction, perception of 
usefulness and willingness to eventually continue this self-measurement practice 
 
- Percentage of measurements performed (compliance to the protocol) 
 
- Percentage of measurements well performed and errors in measurements 
 
- Patients’ systolic and diastolic blood pressure evolution 
 














V. Results analysis and discussion 
 
a. Patients’ characteristics 
 
Ten patients were screened but two out of the ten patients were not recruited. One patient 
refused to participate because of the time that should be invest in the study. The other patient 
didn’t make the necessary proceedings to be added in the platform. In total, 8 patients (50% 
men) were included in the study. The average age was 66.125 ± 12.37 years (range 46-81). The 
mean BMI was 31.83 ± 6.14, 3 patients had a BMI below 25 (37.5%), one patient had a BMI 
between 25 and 29.9 (12.5%) and four patients had a BMI over 30 (50%). A majority of the 
patients (75%) were retired. Half of the patients had a higher education (university or high 
school) as the highest grade obtained.  
 
The majority (87.5%) of patients were diagnosed more than 3 years ago but one of these patient 
is treated only since 1 to 3 years. The most used antihypertensive class of medication were the 
angiotensin conversion enzyme (ACE) inhibitors that were taken by 7 out of 8 patients (87.5%) 
followed by the diuretics taken by 3 out of 8 patients (37.5%). Four patients (50%) are in a 
monotherapy with ACE inhibitor. Two patients are in a polytherapy with ACE inhibitor or 
calcium antagonist combined to a diuretic. Two patients are in a polytherapy with a combination 
of ACE inhibitor, central antihypertensive drug and calcium antagonist or diuretic. Five patients 
take their drugs only in the morning, two patients take their drugs both in the morning and in 
the evening depending on the drug and one patient take the drugs only in the evening. 
 
No patients had a history of myocardial infarction nor stroke which means that all the patients 
are in secondary prevention but two patients (25%) had a history of renal impairment. The 
patients take an average of 5.125 ± 2.80 tablets a day, including the antihypertensive 
medications. The patients visit their general practitioner for arterial hypertension more 
frequently than a specialist (2.62 ± 1.59 times per year vs 0.75 ± 0.7 times per year). Majority 
of the patients (87.5%) already took their blood pressure themselves with arm (57%) or wrist 
(43%) devices. Three patients have a wrist device, which are not preferentially recommended. 
One patient have no device at all. Despite of that, the patients don’t take their blood pressure 
on a regular basis, 3 patients (43%) have a device but never took their blood pressure and four 
patients (57%) took their blood pressure only very few times a month. All these information 
are reported in Table 2. 
 
n 8 
Gender (males) 4 (50%) 
Age (years) 66.125 ± 12.37 
Professional situation (active) 2 (25%) 
Professional situation (inactive) 6 (75%) 
Highest grade (Higher education) 4 (50%) 
Highest grade (High school) 4 (50%) 
Weight (kg) 92.125 ± 25.53 
Height (cm) 170 ± 8.86 
BMI 31.83 ± 6.14 
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BMI < 25 3 (37.5%) 
BMI 25-29.9 1 (12.5%) 
BMI > 30 4 (50%) 
ACE inhibitor 7 (87.5%) 
Diuretics 3 (37.5%) 
Calcium antagonists 2 (25%) 
Central antihypertensive drug 2 (25%) 
Hypertensive since 1 to 3 years 1 (12.5%) 
Hypertensive for more than 3 years 7 (87.5%) 
Treated for AHT since 1 to 3 years 2 (25%) 
Treated for AHT for more than 3 years 6 (75%) 
Diabetics 2 (25%) 
Hypercholesterolemia 4 (50%) 
Tablets per day 5.125 ± 2.80 
Visits to GP for AHT per year 2.62 ± 1.59 
Visits to specialist for AHT per year 0.75 ± 0.7 
Previous history of myocardial infarction 0 
Previous history of stroke 0 
Previous history of renal impairment 2 (25%) 
Previous history of HBPM 7 (87.5%) 
Previous device for HBPM (arm) 4 (57%) 
Previous device for HBPM (wrist) 3 (43%) 
Previous HBPM frequency (never) 3 (43%) 
Previous HBPM frequency (few times a 
month) 
4 (57%) 
Table 2. Patients’ characteristics and clinical features. 
 
 
b. Platform’s functionality and convenience 
 
Regarding the platform’s functionality, some issues were encountered during the two first 
weeks of operation. Indeed, the addition of some of the patients in the system was not correctly 
performed, resulting in the appearance of duplicates in the database. These duplicates had led 
to a data mix up. The database was then cleaned and this issue didn’t occur anymore. 
 
At the first week call, the patients didn’t report new issues and the patients stated that everything 
went fine. After one month, a second call was performed. During this second call, the patients 
didn’t report any issues. Only one patient reported during the first month that there was a 
problem with the device which couldn’t connect anymore to the smartphone. This issue was 
quickly resolved and was not related to the platform’s functionality. 
 
During the last week of follow-up another issue occurred which prevented the data to be 
transferred from the smartphone application to the platform. This issue was due to a slowdown 
in the smartphone application which caused delays, thus causing no data to be sent to the 
platform. This issue is not related to the platform, which was still fully functional, but some 
optimizations need to be made in order to have a more robust system which can support this 
kind of issue. The patients were informed about it and the latest data that have not been 
transferred were retrieved directly from the patients with their authorizations.  
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The last call, at the end of the two month, was not performed but the patients were seen face to 
face directly. This face to face interview allowed the investigator to get the devices back but 
also to collect the patients’ feedback. During this interview, some patients, who were still under 
follow-up during the last week when the issue mentioned above occurred, only reported unsent 
messages and wrong reminders sent due to the issue. Except for the problems of the first and 
for the last week, the patients didn’t report wrong messages received. One patient reported that 
one time he didn’t receive a message when he had taken his blood pressure. Due to that he made 
one more day of measurements during that week. 
 
83,85% (187 out of 223) of the data were treated correctly by the platform. 45 measures 
(20,18%) were not computed among which 8 measures were not computed because of the two 
first weeks issue and 9 measures were not supposed to be computed according to the business 
logic. Indeed, when the data were out of range, the data were not computed, a warning message 
was sent to the patient and a case was created on the expert account. Among these 45 measures, 
18 were not collected by the system because of the last week issue and were retrieved directly 
from the patient during the feedback interview and 2 were sent directly by a patient to the 
investigator because this patient had a connection problem between the smartphone and the 
device but was willing to take the measurements in order to be compliant to the protocol. Beside 
the first and last weeks issues, only 8 measures (4,28%) were not treated correctly by the 































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Based on the data received or not, 80 cases were created in the expert account among which 
16,25% (13 out of 80) were “red” cases (out of range); 48,75% (39 out of 80) were “yellow” 
cases (incomplete measures, missing one day of measurement in a week or no measures done 
at all during the week) and 35% (28 out of 80) were “green” cases (no measures done before 
Wednesday evening or too much measurements in a week). 11,25% (9 out of 80) of these cases 
were abnormal and were not supposed to be created. These abnormal cases came from 
duplicated data during the two first weeks issue. 
 
c. Compliance to the protocol 
 
The patients showed generally a high compliance with 88,5% of compliance to the protocol 
(223 out of 252 measurements done) (Figure 10 and Figure 11). But despite this high 
compliance, the patients didn’t take their measurements at regular moment during the day 
(Figure 12).  
 
One patient was recruited late in the study and thus only performed 7 weeks instead of the two 
months (8 weeks). Only one patient had a low to moderate compliance with 43,75% of measures 
done (14 out of 32) because he initiated the measurements more than one month after his 
recruitment and addition in the platform. The patient was asked why he didn’t initiate the 
measurements on time and he replied that he was abroad for a month without his device. Two 








Figure 12. Patient’s compliance over time. The blue dots represent each measure at which time and date. 
This patient had a 100% compliance but the measures are not made on regular moments. 
 
 
One patient showed a sporadic lack of compliance (23/32 measures made; 71,8% of 
compliance) (Figure 13). During the feedback, the patient said that she was compliant but she 
had difficulties to take her blood pressure with the device. The blood pressure was then taken 
with the help of the investigator. The cuff was correctly placed and inflated correctly but for an 
unknown reason, the device was sometimes unable to give the results. It took several times to 
get a result, which is the reason why the patient sometimes gave up to take her blood pressure. 
The device was then tested successfully on the investigator and the patient reported to have no 
arrhythmia which could be a reason of this issue. According to the “Regulatory information” 
leaflet delivered with the device, other factors than arrhythmia might impact the results such as 
ventricular premature beats, atrial fibrillation, arterial sclerosis, poor perfusion, diabetes, age, 
pregnancy, pre-eclampsia or renal disease (Figure 14). When looking to the patient’s profile, 
renal disease would be the cause of this issue. Another patient also reported having this issue 
once. The use of the device might then not be appropriate for every patients. 
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Figure 13. Patient’s compliance over time. The blue dots represent each measure at which time and date. 
The orange lines represent the lack of compliance. A lack of compliance is considered when there is no 




Figure 14. Regulatory information leaflet delivered with the Nokia BPM (Withings BP-801). 
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Conversely, some patients made more measurements than what was planned. One patient with 
a high compliance (30/32 measures made; 93,75% of compliance) made 6 more periods of 
measurement than asked in the protocol. One of them was made inadvertently, two were made 
because he didn’t receive the message confirming that he took his blood pressure (as mentioned 
before), two were made because he forgot to make a third measurement that was asked by the 
platform and the last one was made because one day he forgot to take his blood pressure in the 





Figure 15. Patient’s compliance over time in a patient with more than 100% compliance. The blue dots 
represent each measure at which time and date. The orange lines represent the lack of compliance. A lack 
of compliance is considered when there is no measures at all in a week, only one measure done in a day or 




There were 77,5% (62 out of 80) of cases which came from a “compliance issue” (green and 
yellow cases) but 67,7% (42/62) of these cases were due to patients taking their blood pressure 
just after the case was created and to the patient who started very late the measurements. 
 
There seems to be no difference in the lack of compliance between the morning and the evening 
with 12 missing measures in the morning and 11 missing measures in the evening. No 






d. Blood pressure evolution 
 
Regarding the blood pressure data, four patients (50%) had very often a blood pressure below 
135/85mmHg. Three patients (37,5%) often had a systolic blood pressure above 140mmHg and 
one patient (12,5%) had a blood pressure that varied a lot. There were only 4 times that a third 
measure was asked (1,79%) which means the measures are concordant (no more than 20mmHg 
in the systolic blood pressure between the first two measures). This can be translated that self-
measurement does not induce stress (otherwise the two measures would be discordant and third 
measurement would be asked more often) and that the devices are technically reliable. 
 
A slight decrease and normalization can be observed in the diastolic blood pressure of four 







Figure 16. Patient’s blood pressure over time. 
 
Some “out of range” cases occurred: one patient with a diastolic blood pressure often below 
60mmHg and another patient with sometimes a diastolic blood pressure above 100mmHg. The 
limits were then change to 90/50mmHg for the upper limit instead of 90/60mmHg and to 
200/110mmHg for the lower limit instead of 200/100mmHg. These changes were performed 
according to the literature [30]. 
 
When comparing the measures above the limits for arterial hypertension during the first month 
versus the measures during the second month, there is a decrease in both systolic and diastolic 
blood pressure after the first month (37 vs 25 measures above the limits for the systolic blood 
pressure and 40 vs 35 measures above the limits for the diastolic blood pressure). However the 
sample size is too small to determine if it’s significant or not. This might also means that the 
patients’ blood pressure is not well controlled under their treatment. 
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One patient with several co-morbidities (hypercholesterolemia, diabetes and renal impairment) 
and who does not take her blood pressure before the study, is very compliant (Figure 17A) and 
had a controlled blood pressure, especially for the second month (Figure 17B). This reflect a 





































Figure 17. Patient’s compliance (A) and blood pressure (B) over time. 
 
 
One patient had a blood pressure that varied a lot (Figure 18). The blood pressure peaks 
occurred every time in the evening. This patient is in a polytherapy with a combination of a 
diuretic, a central anti-hypertensive drug and an ACE inhibitor. All these drugs are taken in the 
evening. A potential explanation is related to the half-life of the drugs, that are efficient at night 
and during the day but that the efficiency decrease at the end of the day, which explain the 
blood pressure peaks in the evening. This means that the information provided by the Suite can 




Figure 18. Patient’s blood pressure over time in a patient with a not well adapted treatment regimen. 
 
One patient once had a high increase of his blood pressure (185.5/109mmHg) in the morning. 
The investigator contacted him immediately in order to assess any symptoms resulting from 
this elevated blood pressure and to know what the circumstances of his blood pressure 
measurement were. The patient reported no symptoms and stated that he felt healthy but he 
reported that he was lacking of anti-hypertensive medication since few days. The patient was 
advised to see his general practitioner and to get a refill of medication later that day. In the 
evening, his blood pressure was decreased to more acceptable levels (148.5/93mmHg) and has 
decreased again 4 days later to normal values (127/84.5mmHg) (Figure 19). 
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Figure 19. Patient’s blood pressure over the time. The red arrow shows the highly elevated blood pressure 
which triggered a call from the investigator to the patient. The blood pressure decreased afterwards since 
the patient had taken his medication. 
 
 
e. Patients’ feedback 
 
The patients were seen face to face to answer the feedback questionnaire. 7 out of 8 patients 
(87,5%) found the study very useful and were also ready to extend this practice. 5 out of 8 of 
patients (62,5%) were very confident in this system, the three others (37,5%) were moderately 
confident. The patients found the devices easy to use but two patients reported having 
difficulties with the cuff that was stiff and two other patients reported that sometimes the device 
couldn’t get their blood pressure and they had to try 3 or 4 more times in order to get a measure. 
All the patients found the smartphone application convenient.  
 
Four patients (50%) shared their data with their general practitioner and for two of them the 
practitioner was glad to see that they show a white coat phenomenon but didn’t have 
hypertension at home. Using such an enabling suite might avoid escalation in the treatment of 
patients presenting with a white coat hypertension. The patients didn’t shared the data with their 
cardiologist neither with their pharmacist. Only one patient had a treatment modification during 
the study. Four patients (50%) were indifferent to the fact of taking their blood pressure 
themselves but the four others were reassured while taking it because it would confirm that they 
only have a white coat effect but no hypertension at home. 
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Seven patients (87,5%) agreed that the self-measurements with the help of the smartphone 
application and the platform might help them to have a better control of their blood pressure. 
All the patients would recommend this system to a relative and five patients (62,5%) were ready 
to pay to use this system for up to 10€ per month. 
 
As other remarks, one patient found the device bulky and thus difficult to transport if we go on 
holiday. The patient also stated that the reminders on Wednesday and Sunday are too early in 
the evening. Another patient reported that some messages received in case of problem might be 
stressful for the patients and should then be adapted. 
 
VI. Conclusion and perspectives 
 
The primary endpoint of the platform’s convenience in terms of functionality, feasibility and 
performance is achieved. Indeed, beside the first week issue (which was rapidly corrected), a 
large majority of the data were correctly treated and the patients didn’t reported any serious 
issue. The platform still need some improvements and adaptations to be more robust and to 
correspond more to the patient’s demand. 
 
The patient compliance to the protocol was high during the study. Some patients even made 
extra measures. The level of compliance is not different between the morning and evening 
measures. However, the patient didn’t take their blood pressure on regular moments, a routine 
should then be implemented via some adaptations in the schedule of measurements and 
reminders sent to the patients. No difference were seen in the compliance between the first and 
second month nor in patients with a different degree of education. 
 
Regarding the blood pressure evolution, some interesting observations and hypothesis can be 
draw. The significance couldn’t be calculate with this small study population but there seems 
to be a trend. Indeed, the blood pressure seems to be better controlled after 1 month of self-
measurement with a slight decrease in systolic and diastolic blood pressure. Moreover, this 
system allowed the investigator to intervene quickly on a patient with a highly elevated blood 
pressure and who didn’t take his antihypertensive drugs to advise him to take his drugs. The 
platform also highlighted a patient with an inadequate treatment regimen. These cases can be 
transposed in real life and reflect the benefits of such system. 
 
The patients found this system very useful and helpful. They were ready to continue this 
practice and found that this system might help to have a better blood pressure control. Some 
patients’ general practitioners were reassured that their patients presents white coat 
hypertension but that their blood pressure is controlled at home. 
 
A further study is then envisaged to evaluate the benefit of such system in non or poor adherent 
hypertensive patients. In parallel, Yatabe et al. (2018) are conducting a study in which they 
compare traditional care to telemedicine in hypertensive patients using HBPM. They will 
compare a control group (traditional care with office visit) to a telemonitoring group (HBPM 
34  
with office visits) and to a telemedicine group (HBPM without office visits and physician 
assessment by mail) [31]. If the use of telemedicine and our system is proved to be superior to 
traditional care, it may have a serious impact on the way to treat hypertensive patients and on 
the medical costs of such condition. 
 
The pharmacist might also have a role in blood pressure control among hypertensive patients. 
Indeed, the HyperLink study assessed whether a pharmacist case management in combination 
with home telemonitoring of blood pressure improves the blood pressure control compared to 
usual care in uncontrolled hypertensive patients [30]. This study is a two-arm randomized 
trial. The intervention arm consists in HBPM in combination with a pharmacist case 
management. The pharmacist will first review the medical history of the patients before 
teaching them about the arterial hypertension and eventually instruct them on how to use the 
telemonitoring device. The pharmacist will then receive all the measures from the patients and 
is allowed to make changes in their medication, to adjust dosage, to order refills or to order 
lab tests in case of adverse effects from the therapy according to the data received. They will 
also discuss and set blood pressure goals with the patients. Phone visits are performed by the 
pharmacist during which they will emphasize on the adherence to therapy and on the patient’s 
lifestyle. The change in medication is only performed when there are less than 75% of blood 
pressure readings that achieved the goal that was set up. The usual care arm consists on 
patients managed by their care providers as usual [30]. 
 
At the end of the study, the intervention group showed a significant improvement in blood 
pressure control and a decrease in blood pressure over 12 months. The intervention group also 
had an increase in medication and a better therapeutic adherence. The benefits persisted for 6 
months after the intervention [32]. An economic evaluation was done in this study. The 
intervention cost 7337$ per person in average with 139$ and 265$ per decreased mmHg for 
the systolic and diastolic blood pressure respectively. There was a non-statistically significant 
decrease of the medical care costs in the intervention group but a significant cost reduction 
might be realised over a long term period. A pharmacist intervention might then be effective 
and implemented without increasing the overall medical care costs [33]. 
 
Another study by Green et al. [34] showed the effectiveness of telemonitoring in combination 
with pharmacist care on blood pressure control. In this study, patients with uncontrolled 
hypertension were divided into three groups: usual care, HBPM with web training and HBPM 
with web training plus a pharmacist care delivered through web communication. The 
pharmacist had to collect medical data from the patients and then decide an “action plan” with 
them. The patients were then contacted on a regular basis by the pharmacist in order to discuss 
about the goals achieved by the patients and their concerns about the treatments. The follow-
up lasted twelve months. The results showed no significant difference between the usual care 
and HBPM with web training but there is a significant improvement in blood pressure control 
in the intervention group applying the pharmacist care. Indeed, there are 25% and 20% more 
patients with controlled blood pressure in this intervention group compared to usual care and 
HBPM with web training respectively [34]. 
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An extension to this study was performed to assess the effectiveness of the intervention one 
year after the completion [35]. All three groups have a better blood pressure control but the 
pharmacist care group still have a better blood pressure control than the two others (usual care 
and HBPM with web training) [35]. The results of these two studies [34, 35] were retranscripted 
by Omboni et al. (Figure 20) [36]. 
 
 
Figure 20. Retranscipted results from Green et al. studies [34, 35] by Omboni et al. [36] showing the 
percentage of patients with controlled blood pressure (<140/90mmHg) among the three study arms after 
12 months follow-up (A) and 12 months after the intervention (B). The pharmacist care group (HBPT + 
web + Pharmacist) shows a greater percentage of patients with controlled blood pressure 
 
Omboni et al. also emphasized the role of the pharmacist in managing chronic disease such as 
arterial hypertension [36]. They can bring a useful clinical expertise and recommendations 
about medications in order to support the physicians. They are involved in long term 
monitoring of the patients and can help them with adherence issues. This bring an 
improvement in patients’ health and well-being, knowledge and satisfaction. As seen in the 
HyperLink study, pharmacists can improve the patients’ education about arterial hypertension, 
they can change their medication and manage the refills. The benefits of this relationship 
between the patients and the pharmacists tended to improve if the pharmacist intervention is 
performed on a regular basis (at least monthly). The white coat effect was also reduced with 
successive and regular visits to the pharmacists comparing to the physician’s office visits. The 
collaboration between the pharmacists and physicians seems to be a good approach for a better 
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Appendix 5. Screenshots from the platform 
 
 
(A) Webpage allowing the addition of a healthcare professional in the system. (B) Webpage 
allowing the addition of a patient in the system. The red arrows represent which buttons to click to 




(A) Information asked when adding a healthcare professional in the system. (B) Information asked 
when adding a patient in the system 
 
 
Care group webpage. The red arrows represent which buttons to click to get to that page and in 
which order 
 
Tracking limits tool in "epertension-admin" account 
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Tool allowing the creation of different types of trackers in the "epertension-config" account 
 
Trackers settings' edition 
 




Questions sets for the General information questionnaire 
 
 
Questions from the "demographic" questions set in the General information questionnaire. 
Different types of questions are available 
 
Question edition menu 
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The blue dots represent each measure at which time and date. The orange lines represent the lack of 
compliance. A lack of compliance is considered when there is no measures at all in a week, only one measure 
done in a day or when there is only one day of measurement in a week. The green lines represent the extra 




Appendix 8. Patient’s blood pressure over time 
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